GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONSTS FOR THE TREATMENT OF NONALOCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS: A META-ANALYSIS AND SYSTEMATIC REVIEW

被引：0
|
作者：
Sayeh, Wasef
Dhoop, Sudheer M.
Sidiki, Sabeen
Beran, Azizullah
Abuhelwa, Ziad
Safi, Mohammad
Alqadi, Mohammad
Sajdeya, Omar
Battepati, Dhanushya
Malhas, Saif-Eddin
Stanely, Sara
Aziz, Muhammad
Alastal, Yaseen
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1569
引用
收藏
页码：S1374 / S1375
页数：2
相关论文
共 50 条
  • [31] Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
    Teshome, Getnet
    Ambachew, Sintayehu
    Fasil, Alebachew
    Abebe, Molla
    HEPATIC MEDICINE-EVIDENCE AND RESEARCH, 2020, 12 : 139 - 151
  • [32] Efficacy of glucagon-like peptide-1 receptor agonists for psoriasis: An updated systematic review and meta-analysis
    Ku, Su-Chi
    Chang, Hua-Ching
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024, 22 (08): : 1148 - 1152
  • [33] Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis
    Berg, Sara
    Stickle, Hannah
    Rose, Suzanne J.
    Nemec, Eric C.
    OBESITY REVIEWS, 2025,
  • [34] EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON BODY COMPOSITION - A SYSTEMATIC REVIEW AND META-ANALYSIS
    Pasam, Ravi Teja
    Bi, Danse
    Jirapinyo, Pichamol
    Thompson, Christopher C.
    GASTROENTEROLOGY, 2024, 166 (05) : S598 - S599
  • [35] Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis
    Shabil, Muhammed
    Khatib, Mahalaqua Nazli
    Ballal, Suhas
    Bansal, Pooja
    Tomar, Balvir S.
    Ashraf, Ayash
    Kumar, M. Ravi
    Sinha, Aashna
    Rawat, Pramod
    Gaidhane, Abhay M.
    Sah, Sanjit
    Daniel, Afukonyo Shidoiku
    Yappalparvi, Ambanna
    Bushi, Ganesh
    BMC ENDOCRINE DISORDERS, 2024, 24 (01)
  • [36] Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy
    Pilar Valdecantos, M.
    Ruiz, Laura
    Pardo, Virginia
    Castro-Sanchez, Luis
    Garcia-Monzon, Carmelo
    Lanzon, Borja
    Ruperez, Javier
    Barbas, Coral
    Naylor, Jaqueline
    Trevaskis, James L.
    Grimsby, Joseph
    Rondinone, Cristina M.
    Valverde, Angela M.
    SCIENTIFIC REPORTS, 2018, 8
  • [37] Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy
    M. Pilar Valdecantos
    Laura Ruiz
    Virginia Pardo
    Luis Castro-Sanchez
    Carmelo García-Monzón
    Borja Lanzón
    Javier Rupérez
    Coral Barbas
    Jaqueline Naylor
    James L. Trevaskis
    Joseph Grimsby
    Cristina M. Rondinone
    Ángela M. Valverde
    Scientific Reports, 8
  • [38] Effects of treatment with Glucagon-like peptide-1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta-analysis
    Wang, Weihao
    Wei, Ran
    Huang, Zhengxiang
    Luo, Jingyi
    Pan, Qi
    Guo, Lixin
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2023, 39 (07)
  • [39] Effects of glucagon-like peptide-1 agonists on non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
    Dong, Yajie
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (SUPP 2) : 4 - 4
  • [40] Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis
    Chen Ding
    Yaxin Tang
    Wenqiang Zhu
    Piaopiao Huang
    Pingan Lian
    Juanli Ran
    Xiansheng Huang
    Acta Diabetologica, 2022, 59 : 519 - 533
12345